Anti-inflammatory effects of the Nigella sativa seed extract, thymoquinone, in pancreatic cancer cells.

BACKGROUND Both hereditary and sporadic forms of chronic pancreatitis are associated with an increased risk of developing pancreatic ductal adenocarcinoma (PDA). Inflammation has been identified as a significant factor in the development of solid tumour malignancies. We have recently shown that thymoquinone (Tq), the major constituent of Nigella sativa oil extract, induced apoptosis and inhibited proliferation in PDA cells. Tq also increased p21 WAF1 expression, inhibited histone deacetylase (HDAC) activity, and induced histone hyperacetylation. HDAC inhibitors have been shown to ameliorate inflammation-associated cancer. In this study, we evaluated the anti-inflammatory potential of Tq in PDA cells in comparison with that of a specific HDAC inhibitor, trichostatin A (TSA). METHODS PDA cells were treated with or without Tq (25-75 microM), with or without pre-treatment of tumour necrosis factor (TNF)-alpha (25 ng/ml). The effect of Tq on the expression of different proinflammatory cytokines and chemokines was analysed by real-time polymerase chain reaction (PCR). Luciferase-labelled promoter studies evaluated the effect of Tq on the transcription of monocyte chemoattractant protein-1 (MCP-1) and nuclear factor-kappaB (NF-kappaB). The effect of Tq on the constitutive and TNF-alpha-induced activation and nuclear translocation of NF-kappaB was examined by ELISA and immunohistochemistry. RESULTS Tq dose- and time-dependently significantly reduced PDA cell synthesis of MCP-1, TNF-alpha, interleukin (IL)-1beta and Cox-2. At 24 h, Tq almost completely abolished the expression of these cytokines, whereas TSA had a less dramatic effect. Tq, but not TSA, significantly and dose-dependently reduced the intrinsic activity of the MCP-1 promoter. Tq also inhibited the constitutive and TNF-alpha-mediated activation of NF-kappaB in PDA cells and reduced the transport of NF-kappaB from the cytosol to the nucleus. CONCLUSIONS Our data demonstrate previously undescribed anti-inflammatory activities of Tq in PDA cells, which are paralleled by inhibition of NF-kappaB. Tq as a novel inhibitor of proinflammatory pathways provides a promising strategy that combines anti-inflammatory and proapoptotic modes of action.

[1]  B. Aggarwal,et al.  Targeting Nuclear Factor-κB Activation Pathway by Thymoquinone: Role in Suppression of Antiapoptotic Gene Products and Enhancement of Apoptosis , 2008, Molecular Cancer Research.

[2]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[3]  F. Balkwill.  TNF-α in promotion and progression of cancer , 2006, Cancer and Metastasis Reviews.

[4]  A. Al-Majed,et al.  Neuroprotective effects of thymoquinone against transient forebrain ischemia in the rat hippocampus. , 2006, European journal of pharmacology.

[5]  P. Szlosarek,et al.  Tumour necrosis factor-α as a tumour promoter , 2006 .

[6]  R. Schneider-Stock,et al.  Thymoquinone extracted from black seed triggers apoptotic cell death in human colorectal cancer cells via a p53-dependent mechanism. , 2004, International journal of oncology.

[7]  Y. Ben-Neriah,et al.  NF-κB functions as a tumour promoter in inflammation-associated cancer , 2004, Nature.

[8]  Michael Karin,et al.  IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer , 2004, Cell.

[9]  N. Chandler,et al.  Increased expression of NF-κB subunits in human pancreatic cancer cells1,2 ☆ , 2004 .

[10]  R. Bold,et al.  Inhibition of AKT abrogates chemotherapy-induced NF-kappaB survival mechanisms: implications for therapy in pancreatic cancer. , 2004, Journal of the American College of Surgeons.

[11]  S. Leach.  Mouse models of pancreatic cancer: the fur is finally flying! , 2004, Cancer cell.

[12]  F. Balkwill,et al.  Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development. , 2004, Oncogene.

[13]  E. Petricoin,et al.  Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. , 2003, Cancer cell.

[14]  P. Allavena,et al.  The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. , 2003, Cancer research.

[15]  R. Schmid,et al.  Mitogenic and antiapoptotic role of constitutive NF‐κB/Rel activity in pancreatic cancer , 2003, International journal of cancer.

[16]  A. Arlt,et al.  Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death , 2003, Oncogene.

[17]  M. Otsuki.  Chronic pancreatitis in Japan: epidemiology, prognosis, diagnostic criteria, and future problems , 2003, Journal of Gastroenterology.

[18]  A. K. Cardozo,et al.  Molecular regulation of monocyte chemoattractant protein-1 expression in pancreatic beta-cells. , 2003, Diabetes.

[19]  Douglas B. Evans,et al.  Function of Nuclear Factor κB in Pancreatic Cancer Metastasis , 2003 .

[20]  Douglas B. Evans,et al.  NF-κB in pancreatic cancer , 2003 .

[21]  Douglas B. Evans,et al.  NF-kappaB in pancreatic cancer. , 2003, International journal of gastrointestinal cancer.

[22]  A. Arlt,et al.  Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. , 2003, Oncogene.

[23]  H. Reber,et al.  Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer , 2003, Molecular Cancer.

[24]  J. Permert,et al.  Resection of Pancreatic Cancer Normalizes the Preoperative Increase of Tumor Necrosis Factor Alpha Gene Expression , 2002, Pancreatology.

[25]  P. Maisonneuve,et al.  Chronic Pancreatitis and Pancreatic Cancer , 2002, Digestive Diseases.

[26]  W. Foulkes,et al.  Risk of pancreatic cancer among individuals with a family history of cancer of the pancreas , 2002, International journal of cancer.

[27]  K. Syrigos,et al.  Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients. , 2001, Anticancer research.

[28]  G. Adessi,et al.  Early detection of pancreatic cancer in patients with chronic pancreatitis: diagnostic utility of a K-ras point mutation in the pancreatic juice , 2001, American Journal of Gastroenterology.

[29]  N. Fausto,et al.  Impaired Preneoplastic Changes and Liver Tumor Formation in Tumor Necrosis Factor Receptor Type 1 Knockout Mice , 2000, The Journal of experimental medicine.

[30]  K. Lillemoe,et al.  Pancreatic cancer: State‐of‐the‐art care , 2000, CA: a cancer journal for clinicians.

[31]  M. Mansour,et al.  Protective effect of thymoquinone against doxorubicin-induced cardiotoxicity in rats: a possible mechanism of protection. , 2000, Pharmacological research.

[32]  G. Kollias,et al.  Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis , 1999, Nature Medicine.

[33]  D. Whitcomb,et al.  Hereditary Pancreatitis and Pancreatic Carcinoma , 1999, Annals of the New York Academy of Sciences.

[34]  Douglas B. Evans,et al.  The Nuclear Factor-κB RelA Transcription Factor Is Constitutively Activated in Human Pancreatic Adenocarcinoma Cells , 1999 .

[35]  J. Abbruzzese,et al.  The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  P. Crooks,et al.  The in vitro anti-tumor activity of some crude and purified components of blackseed, Nigella sativa L. , 1998, Anticancer research.

[37]  G. Stamp,et al.  Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. , 1997, The American journal of pathology.

[38]  E. Dimagno,et al.  Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. , 1997, Journal of the National Cancer Institute.

[39]  Y. Imaizumi.  Longitudinal Gompertzian analysis of mortality from pancreatic cancer in Japan, 1955–1993 , 1996, Mechanisms of Ageing and Development.

[40]  A. Baldwin,et al.  The NF-kappa B and I kappa B proteins: new discoveries and insights. , 1996, Annual review of immunology.

[41]  A. Baldwin,et al.  THE NF-κB AND IκB PROTEINS: New Discoveries and Insights , 1996 .

[42]  A. Krüger,et al.  Promotion of experimental liver metastasis by tumor necrosis factor , 1995, International journal of cancer.

[43]  J. Rüschoff,et al.  Enhancement of experimental metastasis by tumor necrosis factor , 1993, The Journal of experimental medicine.

[44]  K. Panikkar,et al.  Antitumour principles from Nigella sativa seeds. , 1992, Cancer letters.

[45]  K. Panikkar,et al.  Inhibitory effects of Nigella sativa and saffron (Crocus sativus) on chemical carcinogenesis in mice. , 1991, Nutrition and cancer.

[46]  Alan D. Lopez,et al.  Trends in cancer mortality , 1990, The Lancet.

[47]  J. Wittenberg,et al.  Preoperative staging and assessment of resectability of pancreatic cancer. , 1990, Archives of surgery.

[48]  F. Balkwill,et al.  Cells secreting tumour necrosis factor show enhanced metastasis in nude mice. , 1990, European journal of cancer.

[49]  C. la Vecchia,et al.  Trends in cancer mortality in Switzerland, 1951-1984. , 1988, Revue d'epidemiologie et de sante publique.

[50]  G. Emanuelli,et al.  Increased incidence of cancer in chronic pancreatitis. , 1987, Journal of clinical gastroenterology.

[51]  A. Mantovani,et al.  Regulation of the macrophage content of neoplasms by chemoattractants. , 1983, Science.

[52]  T. Rohan,et al.  ALIMENTARY TRACT CANCER MORTALITY IN AUSTRALIA, 1908‐1978: AN EPIDEMIOLOGICAL APPRAISAL , 1981, The Medical journal of Australia.